Company Overview and News
KUALA LUMPUR (Oct 1): Kenanga Investment Bank Bhd (KIBB) has issued four new structured warrants covering the O&G sector, just as Brent crude oil prices surpassed US$80 a barrel this week.
0166 BRDBF 7022 5012 GBTKF 5210
KUALA LUMPUR (Sept 13): The FBM KLCI recovered at midday break, erasing earlier losses, climbing in line with regional peers.
HLFBF UPBMF 7036 1082 BATS 4162 0096 2089 5014 CIMDF 0166 5139 1023 1368 0900 5819 MYPRY 2836
For the full year, Inari’s net profit was up 9.44% to RM249.27mil on the back of a 16.94% increase in revenue to RM1.38bil.
KUALA LUMPUR (Aug 28): Inari Amertron Bhd reported a 13% year-on-year decline in net profit for its fourth quarter ended June 30, 2018 (4QFY18) to RM57.10 million from RM65.53 million, as its profit allocation to non-controlling interests jumped to RM9.76 million versus RM431,000 previously.
KUALA LUMPUR (Aug 6): The Technology Index on Bursa Malaysia was the top gainer on the Malaysian stock exchange as it jumped by 1.04% to 38.85 points following stronger global semiconductor sales during the first half of the year.
0166 8338 AAPL BSMAF 7022 GBTKF 1818
KUALA LUMPUR (July 31): The FBM KLCI retreated in early trade this morning, tracking losses at most regional markets following the overnight bearish close at Wall Street and European markets.
MLYBY SPMXF MLYNF 4065 7113 BC94 SMSN TPGVF 0166 TGLVY 1155 SPMXY 5347 TNABY TNABF SMSD
KUALA LUMPUR (July 30): Inari Amertron Bhd shares fell 4.9 percent, more than any full-day drop since June 11, as Malaysia's benchmark index declined.
KUALA LUMPUR: Maybank Investment Bank Bhd (Maybank IB) has issued 15 new cash-settled call warrants over shares in Bumi Armada Bhd, Eco World Development Group Bhd, Gamuda Bhd, Globetronics Technology Bhd, Hengyuan Refining Co Bhd, IJM Corp Bhd, Inari Amertron Bhd, MyEG Services Bhd, Sime Darby Property Bhd, Sime Darby Bhd, Tenaga Nasional Bhd, Unisem (M) Bhd, VS Industry Bhd, YTL Corp Bhd and the FBM KLCI.
0166 5347 BRDBF 8206 SMEBF TNABY 4197 TNABF 7022 GBTKF 5210
Inari Amertron Bhd (July 25, RM2.44) Maintain buy with a higher fair value of RM2.61: We have revised our financial year 2019 forecast (FY19F) and FY20F earnings marginally upwards by 4.1% and 4.2% respectively after factoring in a slightly higher utilisation rate for its radio frequency (RF) segment. We believe that the segment will continue to grow sturdily on the back of rising RF content in smartphones, which is needed to facilitate the transition from 4G LTE to 5G.
KUALA LUMPUR (July 25): Maybank Investment Bank (IB) Bhd has issued fifteen new European style cash-settled call warrants and one new European style cash-settled put warrant, which were listed today with an issue size of 100 million each.
0166 5347 BRDBF 8206 SMEBF TNABY 4197 TNABF 7022 GBTKF 5210
SINGAPORE (July 20): The ability of companies to deliver on “raised earnings expectations” amid higher bond yields globally is more important than macro economic concerns for the second half of the year, Citigroup analyst Patrick Yau writes in note.
0166 GMALY PBLOF 4715 GMALF 1295
KUALA LUMPUR: Retirement Fund (Inc), also known as Kumpulan Wang Persaraan (Diperbadankan) (KWAP), plans to increase the weightage of equities in its portfolio, as it still has room to increase its allocation of equities, amid uncertainties in the global and domestic markets.
0166 BSMAF 7022 GBTKF 1818
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...